EP0434714A1 - 5-beta-amidomethyle-oxazolidine-2-ones a substitution en position 3 - Google Patents

5-beta-amidomethyle-oxazolidine-2-ones a substitution en position 3

Info

Publication number
EP0434714A1
EP0434714A1 EP89909990A EP89909990A EP0434714A1 EP 0434714 A1 EP0434714 A1 EP 0434714A1 EP 89909990 A EP89909990 A EP 89909990A EP 89909990 A EP89909990 A EP 89909990A EP 0434714 A1 EP0434714 A1 EP 0434714A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
oxazolidin
acetamidomethyl
defined above
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89909990A
Other languages
German (de)
English (en)
Inventor
Steven J. Brickner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0434714A1 publication Critical patent/EP0434714A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to 5'-indolinyloxazolidinones (XI), 3-(fused-ring substituted)phenyl-5 ⁇ -amidomethyloxazolidinones (XXI), 3-(nitrogen substituted)phenyl-5 ⁇ -amidomethyloxazolidinones (LV) which are useful as antibacterial agents.
  • US Patent 4,128,654 discloses 5-halomethylphenyl-2-oxazolidinones which are useful in controlling fungal and bacterial diseases of plants.
  • US Patent 4,250,318 discloses 3-substituted phenyl-5-hydroxy- methyloxazolidinones having antidepressive utility.
  • US Reissue Patent 29,607 discloses 3-substituted phenyl-5- hydroxymethyloxazolidinones having antidepressive, tranquilizing and sedative utility.
  • US Patent 4,340,606 discloses 3-(p-alkylsulfonyl)phenyl-5- (hydroxymethyl or acyloxymethyl)oxazolidinones having antibacterial activity in mammals.
  • Belgium Patent 892,270 discloses 3-(arylalkyl, arylalkenyl or arylacetylenic substituted)phenyl)-5-(aminomethyl)oxazolidinones which are inhibitors of monoamine oxidase.
  • US Patent 4,461,773 discloses 3-substituted phenyl-5-hydroxymethyloxazolidinones which have antibacterial activity.
  • European Patent Publications 127,902 and 184,170 disclose 3- substituted phenyl-5-amidomethyloxazolidinones which have antibacterial utility.
  • Antimicrobial Agents and Chemotherapy 1791 (1987) discusses compounds disclosed in European Patent Publications 127, 902 and 184,170, discussed above, and compares these new compounds with known antibiotics.
  • US Patent 4,705,799 discloses aminomethyloxooxazolidinyl benzene derivatives including sulfides, sulfoxides, sulfones and sulfonamides which possess antibacterial activity.
  • US Patent 4,801,600 discloses 6'-indolinyloxazolidinones (where the indolinyl nitrogen is meta to the oxazolidinone nitrogen) both generically, see formula (I) where "X" is NR 6 and specifically see Example 13.
  • the indolinyloxazolidinones of the present invention are 5'-indolinyloxazolidinones (where the indolinyl nitrogen is para to the oxazolidinone nitrogen).
  • WANG discloses aminomethyl- oxooxazolidinyl cycloalkylbenzene derivatives including cycloalkyl-, alkanone-, hydroxycycloalkyl-, oxime-, amine- and other phenyl- oxazolidinones which possess antibacterial activity. More particularly, WANG discloses alkanone or indanone oxazolidinones generally, see formula (I) where R 1 and R 2 taken together are and specifically, see Examples 16, 26 and 30. All the indanoneoxazolidinones disclosed by WANG require the ketone (-CO-) to be attached directly to the phenyl ring in a position para to the oxazolidinone nitrogen.
  • the indanoneoxazolidinones (XXIB) of the present invention differ from those of WANG.
  • WANG also discloses oximinooxazolidinones, see Example 21 as well as the generic disclosure for R 1 and R 2 taken together to be -NOH.
  • R 1-6 is C 1 -C 4 alkyl
  • NR 1-6 R 1-7 wnere R 1-7 is C 1 -C 3 alkyl and R 1-6 is as defined above, and where R 1-6 an d R 1-7 can be taken together with the attached nitrogen atom to form a saturated mono-nitrogen C 5 -C 7 heterocyclic ring including -O- (morpholine),
  • R 1-8 is C 1 -C 4 alkyl or -CO-R 1-9 where R 1-9 is C 1 -C 4 alkyl or - ⁇ ;
  • R 2-1 is C 1 -C 4 alkyl or - ⁇ ,
  • R 2-1 is as defined above
  • R 2-2 and R 2-3 are the same or different and are -H, C 1 -C 3 alkyl, or R 2-2 and R 2-3 are taken together with the attached nitrogen atom to form a saturated mono-nitrogen C 3 -C 6 heterocyclic ring optionally containing -O-,
  • R 2-4 and R 2-5 are the same or different and are -H and C 1 -C 3 alkyl, -NH-CO-R 2-6 where R 2-6 is C 1 -C 4 alkyl or - ⁇ ,
  • R 5-2 is C 1 -C 4 alkyl or - ⁇ ,
  • R 5-2 is as defined above
  • R 5-3 and R 5-4 are the same or different and are -H, C 1 -C 3 alkyl, or R 5-3 and R 5-4 are taken together with the attached nitrogen atom to form a saturated mononitrogen C 3 -C 6 heterocyclic ring optionally containing -O-,
  • R 5-5 and R 5-6 are the same or different and are -H and C 1 -C 3 alkyl
  • R 5-2 is as defined above
  • R 5-2 is as defined above, -COOH,
  • R 5-11 is C 1 -C 6 alkyl, - ⁇ optionally substituted with 1-4 -F, 1-3 -Cl, 1 -OCH 3 , -OH, -NH 2 , -NO 2 , -CO-CH 3 , -SO 2 -CH 3 and -SO 2 -OH,
  • R 5-13 is -H or -CH 3 and R 5-12 is C 1 -C 6 alkyl, - ⁇ optionally substituted with 1 or 2 -OH, -OCH 3 , -NO 2 , -NH 2 , -Cl, -F, -NH-CH 3 and -N(CH 3 ) 2 ,
  • R 5-14 is -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 )2, -CHCH 3 -CH 2 -CH 3 , -CH 2 -OH, -CH(OH)-CH 3 , -CH 2 - ⁇ , -CH 2 - ⁇ -OH, -CH 2 -SH, -CH 2 -CH 2 -S-CH 3 , and -CH 2 -COOH,
  • R 6 is -H and C 1 -C 3 alkyl and pharmaceutically acceptable salts thereof.
  • Xl is -CO-CH 3 , -CO-O-C(CH 3 ) 3 , -CO-O-CH 2 - ⁇ and -CO-O-(CH 2 ) 2 - Si(CH 3 ) 3 ,
  • R 6 is -I, -N 3 and -NH 2 and where R 2 , R 3 and R 4 are as defined above, and salts thereof.
  • Disclosed are 3-(fused-ring substituted)phenyl-5 ⁇ -amidomethyl- oxazolidin-2-ones of formula (XXI) where
  • R 1-4 is C 1 -C 4 alkyl
  • R 1-5 is C 1 -C 3 alkyl and R 1-4 is as defined above, and where R 1-4 and R 1-5 can be taken together with the attached nitrogen atom to form a saturated mono-nitrogen C 5 -C 7 heterocyclic ring including -O- (morpholine),
  • n 3 and n 4 are 0-3, n 7 and n 8 are 0 or 1
  • R 10-1 and R 10-2 are the same or different and are -H, C 1 -C 3 alkyl and where R 10-1 and R 10-2 taken together with the carbon atom to which they are attached form spirocyclopropyl
  • R 10-1 or R 10-2 is not -H
  • R 5-2 is C 1 -C 4 alkyl or - ⁇ , -O-R 5-2 where R 5-2 is as defined above,
  • R 5-3 and R 5-4 are the same or different and are -H, C 1 -C 3 alkyl, or R 5-3 and R 5-4 are taken together with the attached nitrogen atom to form a saturated mononitrogen C 3 -C 6 heterocyclic ring optionally containing -O-,
  • R 5-5 and R 5-6 are the same or different and are -H and C 1 -C 3 alkyl
  • R 5-2 is as defined above
  • R 5-2 is as defined above, -COOH,
  • R 5-9 is -H or R 5-8 as defined above and where the R 5-9 's can be taken together with the attached nitrogen atom to form a saturated mononitrogen C 3 -C 6 heterocyclic ring optionally containing -O- or -NH- ,
  • R 5-10 is C 1 -C 6 alkyl
  • R 5-11 is C 1 -C 6 alkyl, - ⁇ optionally substituted with 1-4 -F, 1-3 -Cl, 1 -OCH 3 , -OH, -NH 2 , -NO 2 , -CO-CH 3 , -SO 2 -CH 3 and -SO 2 -OH,
  • R 5-14 is -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 ) 2 , -CHCH 3 -CH 2 -CH 3 , -CH 2 -OH, -CH(OH)-CH 3 , -CH 2 - ⁇ , -CH 2 - ⁇ -OH, -CH 2 -SH, -CH 2 -CH 2 -S-CH 3 , and -CH 2 -COOH,
  • R 6 is -H and C 1 -C 3 alkyl and pharmaceutically acceptable salts thereof.
  • - ⁇ optionally substituted with 1-3 -OH, -OCH 3 , -OC 2 H 5 , -NO 2 , -F, -Cl, -Br, -COOH and -SO 3 H, -N(R 1-1 )(R 1-2 ) where R 1-1 and R 1-2 are the same or different and are -H, C 1 -C 2 alkyl,
  • R 1-3 is C 1 -C 4 alkyl
  • R 1-4 is C 1 -C 3 alkyl and R 1-3 is as defined above, and where R 1-3 and R 1-4 can be taken together with the attached nitrogen atom to form a saturated mono-nitrogen C 5 -C 7 heterocyclic ring including -O- (morpholine),
  • R 1-5 is C 1 -C 4 alkyl or -CO-R 1-6 where R 1-6 is C 1 -C 4 alkyl or - ⁇ ;
  • R 2-1 is C 1 -C 4 alkyl or - ⁇
  • R 2-1 is as defined above
  • R 2-2 and R 2-3 are the same or different and are -H, C 1 -C 3 alkyl, or R 2-2 and R 2-3 are taken together with the attached nitrogen atom to form a saturated mono-nitrogen C 3 -C 6 heterocyclic ring optionally containing -O-,
  • R 2-4 and R 2-5 are the same or different and are -H and C 1 -C 3 alkyl
  • R 2-6 is C 1 -C 4 alkyl or - ⁇
  • R 5-2 is C 1 -C 4 alkyl or - ⁇ , -O-R 5-2 where R 5-2 is as defined above,
  • R 5-3 and R 5-4 are the same or different and are -H, C 1 -C 3 alkyl, or R 5-3 and R 5-4 are taken together with the attached nitrogen atom to form a saturated mononitrogen C 3 -C 6 heterocyclic ring optionally containing -O-,
  • R 5-5 and R 5-6 are the same or different and are -H and C 1 -C 3 alkyl
  • R 5-2 is as defined above
  • R 5-2 is as defined above, -COOH,
  • R 5-9 is -H or R 5-8 as defined above and where the R 5-9 's can be taken together with the attached nitrogen atom to form a saturated mononitrogen C 3 -C 6 heterocyclic ring optionally containing -O- or -NH- ,
  • R 5-10 is C 1 -C 6 alkyl
  • R 5-11 is C 1 -C 6 alkyl, - ⁇ optionally substituted with 1-4 -F, 1-3 -Cl, 1 -OCH 3 , -OH, -NH 2 , -NO 2 , -CO-CH 3 , -SO 2 -CH 3 and -SO 2 -OH,
  • R 5-13 is -H or -CH 3 and R 5-12 is C 1 -C 6 alkyl, - ⁇ optionally substituted with 1 or 2 -OH, -OCH 3 , -NO 2 , -NH 2 , -Cl, -F, -NH-CH 3 and -N(CH 3 ) 2 ,
  • R 5-14 is -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 ) 2 , -CHCH 3 -CH 2 -CH 3 , -CH 2 -OH, -CH(OH)-CH 3 , -CH 2 - ⁇ , -CH 2 - ⁇ -OH, -CH 2 -SH, -CH 2 -CH 2 -S-CH 3 , and -CH 2 -COOH,
  • R 6 is -H and C 1 -C 3 alkyl
  • R 5 is as defined above and R 6 is -H, C 1 -C 6 alkyl, -SH, -S-CH 3 , -S-C 2 H 5 , -S- ⁇ , -S-OCH 3 , -S-O- ⁇ , -SO 2 -CH 3 and -SO 2 - ⁇
  • the 5'-indolinyloxazolidin-2-ones (XI) are prepared starting with the corresponding 5-nitroindolines (I). It is preferred that R 2 , R 3 and R 4 all be -H.
  • the indolinyl nitrogen of the 5-nitroindolines (I) is protected to produce the corresponding protected 5- nitroindolines (II).
  • Suitable protecting agents, X 1 include t- butyloxycarbonyl (BOC) , acetyl, -CO-O-CH 2 - ⁇ and -CO-O-(CH 2 ) 2 - Si(CH 3 ) 3 . It is preferred that X 1 be t-butyloxycarbonyl.
  • the nitro group of the protected 5-nitroindolines (II) is reduced with hydrogen and an appropriate catalyst such as palladium on carbon to the corresponding protected 5-aminoindolines (III).
  • an appropriate catalyst such as palladium on carbon
  • CBZ carbobenzyloxy
  • Suitable bases include sodium hydride, sodium methoxide, potassium tertiary butoxide and lithium diisopropylamide; preferred is sodium hydride.
  • the N-allyl- N-CBZ compounds (V) are cyclized to form the oxazolidinone nucleus by reaction with an electrophilic agent. Suitable electrophilic agents include bromine and iodine; iodine in chloroform is preferred.
  • the oxazolidinone nucleus formed is the protected 5-iodomethyloxazolidin- 2-one (VI).
  • the desired side chain at the 5-position is formed by reacting the protected 5-iodomethyl oxazolidinones (VI) with an azide to form the protected azides (VII).
  • the protected azides (VII) are reduced with hydrogen in the presence of a catalyst such as palladium or by P ⁇ 3 or H 2 S or other methods known to those skilled in the art to give racemic protected 5-aminomethyloxazolidin-2-ones (VIII).
  • the racemic compounds can be resolved at the aminomethyloxazolidinone (VIII) stage using methods known to those skilled in the art, see for example, Optical Resolution Procedures for Chemical Compounds, Vol 1,: Amines and Related Compounds, Paul Newman, Optical Resolution Information Center, Manhattan College, Riverdale, NY, 10471, 1978.
  • an optically active acid such as (+) -tartaric acid or alternatively with (-)-tartaric acid
  • optically active acids include, (-) dibenzoyltartaric acid, (+) -camphoric acid, (+)- and (-) -malic acid and (+)-camphor-10-sulfonic acid.
  • dibenzoyltartaric acid (+) -camphoric acid
  • (+)- and (-) -malic acid (+)-camphor-10-sulfonic acid.
  • R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -OCH 3 and -CHCl 2 ; it is more preferred that R 1 is -CH 3 .
  • R 5 is -CH 3 , -CH 2 - CH-CH 2 , -CHO, -CO-R 5-1 where R 5-1 is -CH 3 , -C 2 H 5 , -CHCl 2 , -CH 2 -OH and 2-thienyl.
  • XXI 3-(fused-ring substituted)phenyl-5 ⁇ -amidomethyloxazolidin-2- ones
  • the 3-(fused-ring substituted)phenyl-5 ⁇ -amidomethyloxazolidin-2- ones (XXI) of the present invention include the fused alkanonephenyl- oxazolidinones (B), the fused cycloalkenylphenyloxazolidinones (D), and the fused oximinocycloalkylphenyl-oxazolidinones (E), see CHART C. It is preferred that the 3- (fused-ring substituted)phenyl-5 ⁇ - amidomethyloxazolidinones (XXI) are the fused alkanonephenyloxazolid- inones (B) and the fused oximinocycloalkylphenyloxazolidinones (E). It is more preferred that the 3-(fused-ring substituted)phenyl- 5 ⁇ - amidomethyloxazolidin-2-ones (XXI) are the fused alkanonephenyl- oxazolidin-2-ones (B).
  • the oxazolidinone nucleus is formed by starting with an appropriately substituted aniline (XV) containing the desired R 2 /R 3 /R 4 moiety (see CHART C) or one which can readily be transformed to the desired moiety.
  • the oxazolidinone ring system is synthesized after protecting the aniline (XV) nitrogen with a carbobenzyloxy (CBZ) group. Acylation of the aniline (XV) nitrogen atom gives the urethane (XVI).
  • Suitable bases include sodium hydride, sodium methoxide, potassium tertiary butoxide and lithium diisopropylamide; preferred is sodium hydride.
  • the N-allyl-N-CBZ compound (XVII) is cyclized to form the oxazolidinone nucleus by reaction with an electrophilic agent. Suitable electrophilic agents include bromine and iodine; iodine in chloroform is preferred.
  • the oxazolidinone nucleus formed is the 5- iodomethyloxazolidin-2-one (XVIII).
  • the oxazolidinone ring When the phenyl substituent contains a chiral center then the oxazolidinone ring has two different substituents at the C 5 position and therefore produces two diastereomers. These can be separated by crystallization or chromatography. Following formation of the oxazolidinone ring, the desired side chain at the 5-position is formed by reacting the iodomethyloxazolidin-2-one (XVIII) with an azide to form the azide (XIX).
  • R 1 is -H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -OCH 3 , -CHCl 2 and -CH 2 Cl; it is more preferred that R 1 is -CH 3 .
  • This process is operative regardless of whether the 3-(fused- ring substituted)phenyl-5-amidomethyloxazolidin-2-one (XXI) has a five or six member ring attached to the phenyl group.
  • Both the 2,3- and 3,4- indanyl (5 member alkyl ring) and the 2,3- and 3,4- six member alkyl rings of the fused cycloalkylphenyloxazolidin-2-ones are prepared by starting with the appropriately substituted aniline (XVA). It is preferred that n 2 is 3 or 4.
  • the 2,3- and 3,4- fused alkanonephenyloxazolidin-2-ones are prepared following the procedure for the preparation of the fused cycloalkylphenyloxazolidin-2-ones (XXIA).
  • the alkyl aniline intermediate (XVA) is first oxidized to the corresponding alkanone aniline (XVB) by known procedures. See for example, J. Org. Chem., 27, 70 (1962).
  • the amino group is protected, for example as the acetamide, and then the protected aniline (XVA) is oxidized to the corresponding protected alkanone aniline (XVB) with an oxidizing agent such as chromium trioxide in acetic acid and acetone.
  • the deprotected alkanonephenyl aniline (XVB) is then reacted just as the corresponding alkyl aniline (XVA) to produce the corresponding alkanone (XXIB) . It may be necessary to protect the ketone functionality as the ketal with ethylene glycol, for example, followed by deprotection with acid treatment at a later-stage.
  • the fused cycloalkylphenyloxazolidin-2-one (XXIA) product can be oxidized with an oxidizing agent such as chromium trioxide in acetic acid and acetic anhydride directly to the corresponding fused alkanonephenyloxazolidin-2-one (XXIB) product.
  • an oxidizing agent such as chromium trioxide in acetic acid and acetic anhydride directly to the corresponding fused alkanonephenyloxazolidin-2-one (XXIB) product.
  • the compounds are prepared by either starting with the appropriately substituted aniline intermediate (XVB) or by alkylation of the ketone (XXIB) or enamine (XXIH) at a later stage in the synthesis as is known to those skilled in the art.
  • XVB appropriately substituted aniline intermediate
  • XXIB alkylation of the ketone
  • XXIH enamine
  • the fused hydroxycycloalkylphenyloxazolidin-2-ones are prepared from the corresponding fused alkanonephenyloxazolidin-2-ones (XXIB) by reduction with a reducing agent such as sodium borohydride, sodium cyanoborohydride, lithium borohydride, lithium tri-secbutylborohydride, etc.
  • a reducing agent such as sodium borohydride, sodium cyanoborohydride, lithium borohydride, lithium tri-secbutylborohydride, etc.
  • XXID fused cycloalkenylphenyloxa- zolidin-2-ones
  • XVID desired amino indene or amino dihydro- naphthalene
  • XXID indenes
  • XXIC indanol
  • Suitable reagents for the dehydration include (CF 3 -CO) 2 O, CH 3 -SO 2 -Cl or (CF 3 SO 2 ) 2 O and triethylamine.
  • Dehydration of a benzylic substituted fused hydroxycycloalkylphenyloxazolidinone (C) will result in the production of just one fused cycloalkenylphenyl- oxazolidinone (D).
  • D fused cycloalkenylphenyl- oxazolidinone
  • the fused oximinocycloalkylphenyloxazolidin-2-ones are prepared from the corresponding fused alkanonephenyloxazolidin-2-ones (XXIB) by reaction with hydroxylamine (R 7 is -H) hydrochloride or a substituted hydroxylamine (R 7 is not -H) hydrochloride in the presence of a base such as pyridine or sodium bicarbonate.
  • XXXII indazolyloxazolidin-2-ones
  • R 2 , R 3 and R 4 all be -H.
  • R 6 is -H or -CH 3 .
  • the indazolyl nitrogen of the nitroindazoles (XXII) is protected, as previously discussed, to produce the corresponding protected nitroin- dazoles (XXIII). It is preferred that X 1 be t-butyloxycarbonyl.
  • the nitro group of the protected nitroindazoles (XXIII) is reduced with hydrogen, as previously discussed, to the corresponding protected aminoindazoles (XXIV).
  • the protected allyl compounds (XXVI) and the bisallyl compounds (XXVI') are cyclized to form the oxazolidinone nucleus by reaction with an electrophilic agent, as previously discussed.
  • the oxazolidinone nuclei, formed are the protected iodomethyloxazolidin-2- ones (XXVII) and the allyliodomethyloxazolidin-2-ones (XXVII').
  • the desired side chain at the 5-position is formed, as previously discussed, to form the azides (XXVIII) and allylazides (XXVIII').
  • the protecting group, X 1 of the iodomethyl compounds (VI) may be lost, see CHART E. In other cases it will be retained and can be removed after the aminomethyl group is acylated.
  • the azides (XXVIII) and allylazides (XXVIII') can be separated but it is preferred to not separate them at this stage but to reduce the mixture.
  • aminomethyloxazolidin-2-ones (XXIX) and allylaminomethyloxa- zolidin-2-ones (XXIX') are then acylated to produce the protected indazolyloxazolidin-2-ones (XXX) , unprotected indazolyloxazolidin-2- ones (XXXI) and allyl indazolyloxazolidin-2-ones (XXX') containing the desired R 1 group at C 5 .
  • the acylation produces the bis acylated compound with the acyl group also at the 1-indazolyl position.
  • R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cyclo- alkyl, -OCH 3 and -CHCl 2 ; it is more preferred that R 1 is -CH 3 .
  • the unprotected indazolyloxazolidin-2-ones (XXXI) are then N- acylated or N-alkylated, if necessary, with the desired R 5 group, either as the acid halide, anhydride, or alkyl halide to produce the desired indazolyloxazolidin-2-ones (XXXII).
  • R 5 is -CH 3 , -CH 2 -CH-CH 2 , -CHO, -CO-R 5-1 where R 5-1 is -CH 3 , -C 2 H 5 , -CHCl 2 , -CH 2 - CN, -CH 2 -OH, -CH 2 -O-CH 3 , -CH 2 -O-CO-CH 3 , -CH 2 -O-CH 2 - ⁇ or 2-thiophene.
  • benzimidazolyloxazolidin-2-ones (XLIII) and the benzotriazolyloxazolidin-2-ones (LIV) are prepared in a similar manner (compare CHARTS F and G) to the indazolyloxazolidin-2-ones (XXXII) (CHART E) with the following exceptions.
  • the allyl group replaced the protecting group (X 1 ) to some extent producing the bisallylindazolyl compounds (XXVI'); with the benzimidazolyloxazolidin-2-ones (XLIII) and the benzotriazolyloxazolidin-2-ones (LIV) the X 1 protecting group is not lost when transforming the urethanes (XXXVI and XLVII) to the protected compounds (XXXVII and XLVIII) respectively.
  • the desired R5 group of the benzimidazolyloxazolidin-2- ones may be the same as the protecting group X 1 in the intermediate precursors (XXXIV-XLI).
  • the protected benzimidazolyloxazolidin-2-ones (XLI) are identical to the benzimidazolyloxazolidin-2-ones (XLIII), and therefore one has obtained the useful end product when obtaining the protected benzimidazolyloxazolidinones (XLI).
  • R 6 is -H or C 1 -C 6 alkyl.
  • the mixture of enantiomers is resolved by means known to those skilled in the art.
  • the enantiomer which is pharmacologically active is the ⁇ -enantiomer, see CHARTS A thru G.
  • the racemic mixture is useful in the same way and for the same purpose as the pure ⁇ -enantiomer; the difference is that twice as much racemic material must be used to produce the same effect as the pure ⁇ -enantiomer.
  • the 5'-indolinyloxazolidin-2-ones (XI), 3- (fused-ring sub- stituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (XXI) and the 3- (nitrogen substituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (LV) of the present invention are useful as antibacterial agents in treating infections in mammals caused by gram-positive and anaerobic infections. It is preferred to treat humans and useful warm-blooded mammals such as cattle, horses, sheep, hogs, dogs, cats, etc.
  • the 5'-indolinyloxazolidin-2-ones (XI), 3-(fused-ring sub- stituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (XXI) and the 3- (nitrogen substituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (LV) of the present invention are also useful in treating AIDS patients infected with Mycobacterium avium.
  • the 5'-indolinyloxazolidin-2-ones (XI), 3-(fused-ring sub- stituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (XXI) and the 3- (nitrogen substituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (LV) can be administered either parenterally (IV, IM, SQ) or orally.
  • the daily dose is about 5 to about 20 mg/kg. This dose can preferrably be given in divided doses and administered 2-4 times daily.
  • the preferred route of administration as well as the particular dosage form for either the parenteral or oral route depends on the particular facts of the situation including the nature of the infection and condition of the patient.
  • the 5'-indolinyloxazolidin-2-ones (XI), the 3-(fused-ring sub- stituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (XXI) and the 3- (nitrogen substituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (LV) can be used either alone or in conjunction with other antibacterial agents as is known to those skilled in the art.
  • the 5'- indolinyloxazolidin-2-ones (XI), the 3- (fused-ring substituted)- phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (XXI) and the 3- (nitrogen substituted)phenyl-5 ⁇ -(amidomethyl)oxazolidin-2-ones (LV) can be used in conjunction with non-antibacterial agents as is known to those skilled in the art.
  • Suitable pharmaceutically acceptable salts include, for example, chloride, sulfate, phosphate, citrate and oxylate.
  • variable sub- stituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis.
  • each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses.
  • both R i and R j are bonded to the preceding carbon atom.
  • Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion.
  • the cyclic molecular fragment, 4- (ethyl) -1-piperazinyl can be represented by -N*-(CH 2 )2-N(C 2 H 5 ) -CH 2 - C*H 2 .
  • a rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound.
  • the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial.
  • the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other.
  • a substituent (X 1 ) which is "below” another substituent (X 2 ) will be identified as being in the alpha ( ⁇ ) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -” or "!.
  • the corresponding substituent attached “above” (X 2 ) the other (X 1 ) is identified as being in the beta ( ⁇ ) configuration and is indicated by an unbroken line attachment to the carbon atom.
  • variable substituent when a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable.
  • a variable R i attached to a carbon atom as
  • R i When a bivalent variable, R i , is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form " ⁇ -R i-j : ⁇ -R i-k " or some variant thereof. In such a case both ⁇ -R i-j and ⁇ - R i-k are attached to the carbon atom to give
  • bivalent variable may be defined as two separate monovalent variable substituents
  • two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable.
  • R i and R 4 may be defined to be taken together to form (1) a second bond between C 1 and C 2 or (2) a bivalent group such as oxa (-O-) and the formula thereby describes an epoxide.
  • the carbon atom content of variable substituents is indicated in one of two ways .
  • the first method uses a prefix to the entire name of the variable such as "C 1 -C 4 ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable.
  • the prefix is separated from the variable by a space.
  • C 1 -C 4 alkyl represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given).
  • the prefix indicates the entire carbon atom content of the variable being defined.
  • C 2 -C 4 alkoxycarbonyl describes a group CH 3 - (CH 2 ) n -O- CO- where n is zero, one or 2.
  • the carbon atom content of only each portion -of the definition is indicated separately by enclosing the "C i -C j " designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined.
  • this optional convention (C 1 -C 3 )alkoxy- carbonyl has the same meaning as C 2 -C 4 alkoxycarbonyl because the "C 1 -C 3 " refers only to the carbon atom content of the alkoxy group.
  • C 2 -C 6 alkoxyalkyl and (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms
  • the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
  • TLC refers to thin-layer chromatography
  • THF refers to tetrahydrofuran
  • THP refers to tetrohydropyanyl
  • DMF refers to dimethylformamide
  • TEA refers to triethylamine
  • Alcohol refers to ethyl alcohol.
  • MPLC refers to medium pressure liquid chromatography
  • Saline refers to an aqueous saturated sodium chloride solution.
  • IR refers to infrared spectroscopy.
  • CMR C-13 magnetic resonance spectroscopy
  • chemical shifts are reported in ppm ( ⁇ ) downfield from TMS.
  • NMR nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm ( ⁇ ) downfield from tetramethyl- silane.
  • TMS refers to trimethylsilyl
  • ⁇ refers to phenyl (C 6 H 5 ).
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit.
  • [M + H] + refers to the positive ion of a parent plus a hydrogen atom.
  • El refers to electron impact.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • the ratios of solvents used are volume/volume (v/v).
  • BOC refers to t-butyloxycarbonyl, -CO-O-C(CH 3 ) 3 .
  • CBZ refers to carbobenzyloxy, -CO-O-CH 2 - ⁇ .
  • Benzyl chloroformate (1.2 ml) is added to a solution of N- acetyl-5-aminoindoline (III, EXAMPLE 2, 1.4 g) and sodium bicarbonate (1.33 g) in acetone/water (40/60, 20 ml) at 0o. The mixture is stirred for 2.5 hr, then benzyl chloroformate (0.5 ml) is added. After stirring for 2.3 hr, the mixture is poured into chloroform (25 ml) and the organic layers are washed with aqueous sodium bisulfate (10%, 2x) and then washed with aqueous sodium carbonate (10%, 2x).
  • the organic layers are combined and dried over magnesium sulfate and concentrated under reduced pressure to a solid which is purified on a 40-63 ⁇ silica column eluting with a gradient from 100% hexane to 100% ethyl acetate.
  • Iodine (1.94 g) is added to a mixture of 1-acetyl-(N-allyl-N- carbobenzyloxy)-5-aminoindoline (V, EXAMPLE 4, 1.3 g) in chloroform (20 ml).
  • Di-tert-butyldicarbonate (13.4 g) is added all at once to a solution of 5-nitroindoline (I, 5.00 g) in freshly distilled THF (85 ml). The mixture is refluxed for three days then di-tert-butyldi carbonate (9.90 g) is added and the mixture refluxed overnight. The mixture is poured into water (225 ml), this is extracted with ethyl acetate (4x, total 450 ml). The combined organic layers are washed with aqueous sodium bicarbonte (5%, 500 ml), saline, dried over magnesium sulfate and concentrated under reduced pressure.
  • aqueous sodium bicarbonte 5%, 500 ml
  • saline dried over magnesium sulfate and concentrated under reduced pressure.
  • Benzyl chloroformate (2.1 ml) is added to a mixture of 1-carbo- t-butyloxy-5-aminoindoline (III, EXAMPLE 10, 3.147 g) and sodium bicarbonate (2.40 g) in acetone/water (55/45, 40 ml) at 0o. After stirring for one hour, chloroform (50 ml) is added to the mixture. The mixture is then poured into ethyl acetate (50 ml) and washed with saline. The aqueous layer is then extracted with ethyl acetate (2x for total of 200 ml).
  • Iodine (5.512 g) is added to a mixture of 1-carbo-t-butyloxy-(N- allyl-N-carbobenzyloxy)-5-aminoindoline (V, EXAMPLE 12, 4.190 g) in chloroform (65 ml). After stirring for 3 hr the mixture is poured into chloroform (40 ml), washed with aqueous sodium thiosulfate (10%, 3 x 100 ml), dried over magnesium sulfate and concentrated under reduced pressure to a residue. The residue is passed over a silica column (40-63 ⁇ ) eluting with ethyl acetate/hexane (10/90) then eluted with chloroform.
  • Trifluoroacetic acid (0.250 ml) is added slowly over one minute to a mixture of ( ⁇ )-3-(5'-1-carbo-t-butyloxyindolinyl)-5-(acetamido- methyl)oxazolidin-2-one (IX, EXAMPLE 16, 0.038 mg) in methylene chloride (3 ml). The mixture is stirred for 1.5 hr under nitrogen then poured into saturated aqueous sodium bicarbonate (30 ml). The aqueous mixture is extracted with methylene chloride (3 x for a total of 40 ml). The combined organic extracts are washed with saturated aqueous sodium bicarbonate (10 ml) and the aqueous extracts combined.
  • EXAMPLE 18 ( ⁇ )-3-(5'-1-Isobutyrlindolinyl]-5-(acetamidomethyl)- oxazolidin-2-one (XI) ( ⁇ )-3-(5'-Indolinyl)-5-(acetamidomethyl)oxazolidin-2-one (X, EXAMPLE 17, 53 mg) is dissolved in methylene chloride (1.0 ml). Triethylamine (80 ⁇ l) is added. Isobutyrl chloride (25 ⁇ l) is added slowly over 30 seconds at 0o. After stirring for two hr, the mixture is added to saline (10 ml) and extracted with methylene chloride (6 x for 20 ml total).
  • the combined organic extracts are dried over magnesium sulfate and concentrated to provide a solid.
  • the solid is purified by passing thru a silica cartridge, eluting with chloroform (1 ml) ethyl acetate (4 ml), methanol/ethyl acetate (10/90, 27 ml). The appropriate fractions are pooled and concentrated to give the title compound, mp 200-202o.
  • Di-tert-butyldicarbonate (11.500 g) is added to a mixture of 6- nitroindoline (I, 4.300) in freshly distilled THF (40 ml). The mixture is refluxed for 3 days then poured into water (125 ml) and extracted with ethyl acetate (3x, 220 ml total). The combined organic layers are washed with aqueous sodium bicarbonate (5%), saline, dried over magnesium sulfate and concentrated under reduced pressure to obtain a mixture of a solid in an oil.
  • Iodine (16.84 g) is added to a solution of 3-(carbobenzyloxy)-N- (allyl)-5-aminoindan (XVIIA, EXAMPLE 42, 10.39 g) in chloroform (400 ml) at 20o. The mixture is stirred at 20o for 3.3 hr, then poured into aqueous sodium thiosulfate (10%, 550 ml). The layers are separated and the chloroform layer is dried over magnesium sulfate and concentrated under reduced pressure to give a solid.
  • the mixture is filtered thru diatomaceous earth, washing the pad first with ethyl acetate, then methanol/ethyl acetate (10/90). The filtrate is concentrated under reduced pressure to give a solid. This is deemed of sufficient quality for further use.
  • Acetic anhydride (1.5 ml) is added to a solution of ( ⁇ )-3-(5'- indanyl)-5-(aminomethyl)oxazolidin-2-one (XXA, EXAMPLE 45, 0.472 g) in pyridine (3.0 ml) over a period of 2 ain with a slight exotherm. The mixture is stirred at 20-25o for 21 hr, then concentrated under reduced pressure to give an oil. The oil is transferred to a Erlenmeyer flask (50 ml) containing chloroform (10 ml) and ethyl acetate (20 ml) is added.
  • Benzoyl chloride (0.31 g, 0.26 ml) is added to a solution of ( ⁇ ) -3- (5 ' -indanyl) -5- (aminomethyl)oxazolidin-2-one (XXA, EXAMPLE 45 , 0.518 g) in pyridine (4.0 ml) at 0o tinder argon over a period of 1 min.
  • the mixture is stirred at 0o for about 1 hr, then allowed to warm to 20-25o for a total of 23 hr.
  • TLC analysis showes residual starting material, so benzoyl chloride (0.1 ml) is added after again cooling to 0o, and after 5 hr the reaction is complete.
  • Triethylamine (56 ⁇ l) followed by methyl chloroformate (36 ⁇ l) is added to a mixture ( ⁇ )-3-(5'-indanyl)-5-(aminomethyl)oxazolidin-2- one (XXA, EXAMPLE 45, 0.085 g) in methylene chloride (3.0 ml) under argon at 0o.
  • the mixture is stirred at 0o for 45 min, then allowed to warm to 20-25o. After a total of 19 hr, the mixture is concentrated under reduced pressure to give a residue.
  • the mixture is extracted with ethyl acetate (5 x 200 ml), then with methylene chloride (3 x 200 ml).
  • the extracts are washed with saline, dried over magnesium sulfate, and concentrated under reduced pressure to give an oil.
  • the oil is taken up in chloroform and concentrated under reduced pressure to give a solid.
  • a portion of the solid is purified by silica gel flash chromatography (0.5 x 5 cm column, eluting with chloroform, then ethyl acetate, followed by a gradient of methanol-ethyl acetate.
  • a mixture of 5-nitroindazole (XXII, 5.685) and di-t-butyl di- carbonate (15.325 g) is stirred for four days in refluxing THF (freshly distilled, 220 ml) tinder nitrogen. The mixture is then concentrated to 70 ml, by distillation, and then poured over crushed ice (600 ml). After the ice melts, the mixture is filtered using reduced pressure. The precipitate is dried in a vacuum oven to give a solid.
  • the oil is passed over a silica column (27 x 4.5 cm, 40-63 ⁇ ) eluting with ethyl acetate/hexane (1/3, 500 ml followed by 1/1 1000 ml), ethyl acetate (1000 ml) and methanol/ethyl acetate (1/9, 1000 ml).
  • Benzyl chloroformate (2.45 ml) is added to a mixture of 1-carbo- t-butyloxy-5-aminoindazole (XXIV, EXAMPLE 58, 3.760 g) and sodium bicarbonate (2.721 g) in acetone/water (1/1, 50 ml) at 0o over one minute. The mixture is stirred under nitrogen for 1.5 hr then poured into water (50 ml). The aqueous mixture is then extracted with ethyl acetate (3 x, 250 ml total).
  • Allyl bromide (1.70 ml) is added to a mixture of 1-carbo-t- butyloxy-5-(N-carbobenzyloxy)aminoindazole (XXV, EXAMPLE 59, 5.805 g) and sodium hydride/mineral oil (50% by weight, 1.000 g, 15.8 mmol sodium hydride) in freshly distilled THF (80 ml). The mixture is refluxed for 20 hr under nitrogen, then poured into water (100 ml). The aqueous mixture is extracted with ethyl acetate (3 x 100 ml). The combined organic layers are washed with saline, dried over magnesium sulfate, and concentrated to an oil .
  • the oil is passed over a silica gel column (26 x 4.5 cm, 40-63 ⁇ ), eluting with ethyl acetate/hexane (1/4 2 1, 1/1 11) and ethyl acetate (300 ml) collecting 47 ml fractions.
  • Iodine (4.699 g) is added to 3.580 g of a mixture of 1-carbo-t- butyloxy-5-(N-allyl-N-carbobenzyloxy) aminoindazole (XXVI, EXAMPLE 60) and 1-allyl-5-(N-allyl-N-carbobenzyloxy)aminoindazole (XXVI', EXAMPLE 60) in chloroform (95 ml).
  • the mixture is stirred under nitrogen for 1.5 hr then poured into aqueous sodium thiosulfate (10%, 100 ml). The layers are separated, and the organic layer is washed with additional aqueous sodium thiosulfate (10% , 2 x 50 ml).
  • aqueous layers are combined and extracted with ethyl acetate (3 x, 200 ml total).
  • the organic layers are combined, dried over magnesium sulfate and concentrated to give an oil.
  • the oil is adsorbed onto silica gel (40-63 ⁇ ) then placed on a silica gel column (35 x 5.5 cm, 40-63 ⁇ ) eluting with ethyl acetate/:hexane (1/3, 500 ml; 1/1, 2 1) and methanol/ethyl acetate (1/9, 2 1) collecting 41 ml fractions.
  • the crude material is dissolved and is passed over a silica gel column (23 x 4 cm, 40-63 ⁇ ) eluting with methanol/chloroform (1/9, 600 ml, 1/4, 1.5 1) collecting 46 ml fractions.
  • Acetic anhydride (0.5 ml) is added to ( ⁇ )-3-(5'-indazolyl)-5- (aminomethyl)oxazolidin-2-one (XXIX, EXAMPLE 63, 152 mg) in pyridine (1,5 ml) at 0o. The mixture is stirred for two hr while allowing it to warm to 20-25o. The mixture is then concentrated under reduced pressure to a solid.
  • Acetic anhydride (0.5 ml) is added to ( ⁇ )-3-[5'-(1-n-propyl- indazolyl)]-5-(aminomethyl)oxazolidin-2-one (XXIX', EXAMPLE 63, 126 mg) in pyridine (1.5 ml) at 0o. The mixture is stirred for two hr while allowing it to warm to 20-25o. The mixture is then concentrated under reduced pressure to a solid.
  • aqueous sodium bicarbonate solution (0.137 g/ml) is very slowly added to a solution of 1-ethyl-2-methyl-5-aminobenzimidazole hydrochloride (XXXV, 9.715 g) in water (50 ml).
  • a precipitate formes from the effervescent mixture.
  • the precipitate is dissolved by adding acetone (50 ml), and remained in solution after adding another 70 ml of the sodium bicarbonate solution (13.667 g sodium bicarbonate total).
  • benzylchloroformate (5.7 ml) is added slowly over two min. The mixture is then slowly warmed to 20-25o.
  • acetone is added (100 ml) to dissolve a precipitate that is formed.
  • benzylchloroformate 150 ⁇ l is added.
  • the mixture is poured into ethylacetate.
  • the layers are separated, and the aqueous phase is extracted with ethyl acetate, 4 x.
  • the combined organic layers are washed with aqueous sodium bisulfate (10%, 2 x), which removed the color.
  • the desired product is in the aqueous sodium bisulfate washings.
  • These aqueous layers are made alkaline (pH -14) with sodium hydroxide (5N). A solid is obtained after filtering the alkaline mixture.
  • Iodine (25.372 g) is added to a mixture of 1-ethyl-2-raethyl-(N- allyl-N-carbobenzyloxy)-5-aminobenzimidazole (XXXVII, EXAMPLE 68, 7.790 g) in chloroform (200 ml). After 25 min the mixture is poured into aqueous sodium thiosulfate (10%, 100 ml) and the layers are separated. The organic layer is washed again with sodium thiosulfate (10%, 3 x, 250 ml total). The organic phases are combined and dried over magnesium sulfate and concentrated to give a solid.
  • the solid is dissolved in methylene chloride and passed over a silica column (36 x 5.5 cm, 40-63 ⁇ ).
  • the column is eluted with a methylene chloride --- ⁇ methanol/methylene chloride (50/50) gradient.
  • the appropriate fractions are pooled and concentrated to provide crude product.
  • the crude desired product is dissolved in chloroform (3 ml) and passed over a silica gel column (27 x 4.5 cm, 40-63 ⁇ ).
  • the column is eluted with ethyl acetate (2 1), methanol/ethyl acetate (10/90, 1 1) and methanol/ethyl acetate (20%, 1 1).
  • the crude sample is placed on a silica gel column (5 cm x 0.5 cm, 40-63 ⁇ ) and eluted with ethyl acetate followed by methanol/ethyl acetate mixtures (1/9 10 ml, 1/3 20 ml, 1/1 20 ml. The 1/3 and 1/1 methanol/ethyl acetate fractions are combined and concentrated to give the title compound as a foamy solid.
  • EXAMPLE 72 ( ⁇ )-3-(5'-1-Ethyl-2-methylbenzimidazolyl)-5-(acetamidomethyl)oxazolidin-2-one (XLI/XLIII) A mixture of ( ⁇ )-3-(5'-1-Ethyl-2-methylbenzimidazolyl)-5-(amino- methyl)oxazolidin-2-one (XL, EXAMPLE 71, 0.100 g) in pyridine (2 ml) and acetic anhydride (1 ml) is stirred under nitrogen for 2 hrs.
  • EXAMPLE 129 ( ⁇ )-3-(1'-Oxo-2' ⁇ -methyl-5'-indanyl)-5 ⁇ -(acet-mido- raethyl)oxazolidin-2-one (XXIB), ( ⁇ )-3-(1'-oxo-2' ⁇ - methyl-5'-indanyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2- one (XXIB) and ( ⁇ )-3-(1'-Oxo-2',2'-dimethyl-5'- indanyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) n-Butyl lithium (1.6 M, 0.92 ml) is added to a solution of diisopropylamine (20 ml) in dry tetrahydrofuran (15 ml) at -78o under nitrogen, and the mixture stirred for 30 ain. Solid ( ⁇ )-3-(1'-oxo-
  • EXAMPLE 130 ( ⁇ )-3-(1'-Oxo-2' ⁇ -ethyl-5'-indanyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) , ( ⁇ )-3-(1'-oxo-2' ⁇ - ethyl-5' -indanyl) -5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) and ( ⁇ )-3-(1'-Oxo-2',2'-diethyl-5'-indanyl)-5 ⁇ - (acetamidomethyl)oxazolidin-2-one (XXIB) Following the general procedure of EXAMPLE 129 and making noncritical variations but using ethyl iodide (72 ⁇ l), permiting the mixture to warm to 20-25o for 18 hr, and the eluting with methanol/- ethyl acetate (7/93)], the title compounds are obtained, N
  • EXAMPLE 132 ( ⁇ )-3-(1'-Oxo-2' ⁇ -methyl-6'-tetralinyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB), ( ⁇ )-3-(1'-oxo-2' ⁇ - methyl-6'-tetralinyl)-5-(acetamidomethyl)oxazolidin-2- one (XXIB) and ( ⁇ )-3-(1'-Oxo-2',2'-dimethyl-6'- tetralinyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB)
  • a sodium hydride/mineral oil dispersion (50%, 66 mg) is added all at once to a solution of ( ⁇ )-3-(1'-oxo-5'-indanyl)-5 ⁇ -(acetamido- methyl)oxazolidin-2-one (XXIB, EXAMPLE 52, 200 mg) in dry tetrahydrofuran (5 ml) at 0o and the mixture stirred for 30 min at 0o. Then excess gaseous formaldehyde is bubbled into the solution via a needle attached to a flask where solid paraformaldehyde is heated.
  • reaction mixture is then allowed to warm to 20-25o for 1 hr and then poured into water and extracted with ethyl acetate 3 times.
  • the combined organic extracts are combined, dried over magnesium sulfate and concentrated under reduced pressure to give a solid.
  • the solid is chromatographed on silica gel (1000 ⁇ ) preparative TLC using a 20 x 20 cm plate, and eluting with methanol/ethyl acetate (5/95) to give the title compounds.
  • EXAMPLE 136 3-(1'-Oxo-2' ⁇ -methyl-5'-indanyl)-5 ⁇ -(acetamidomethyl)- oxazolidin-2-one (XXIB), 3-(1'-oxo-2'0-methyl-5'- indanyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) and 3-(1'-Oxo-2',2'-dimethyl-5'-indanyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB)
  • EXAMPLE 137 3-(1'-Oxo-2'c_-ethyl-5'-indanyl)-5 ⁇ -(acetamidomethyl)- oxazolidin-2-one (XXIB) and 3-(1'-oxo-2'0-ethyl-5'- indanyl) -5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) Following the general procedure of EXAMPLE 130 and making non- critical variations but starting with 3-(1'-oxo-5'-indanyl)-5 ⁇ - (acetamidomethyl)oxazolidin-2-one (XXIB, EXAMPLE 108) the title compounds are obtained.
  • EXAMPLE 139 3-(1'-Oxo-2' ⁇ -methyl-6'-tetralinyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB), 3-(1'-oxo-2' ⁇ -methyl- 6'-tetralinyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XXIB) and 3-(1'-Oxo-2',2'-dimethyl-6'-tetralinyl)-5 ⁇ -
  • EXAMPLE 144 3-(5'-1-(O-Acetyl(hydroxyacetyl)indolinyl))-5 ⁇ - (acetamidomethyl)oxazolidin-2-one (XI) Following the general procedure of EXAMPLE 143 and making non- critical variations but starting with 3-(5'-1-hydroxyacetylindolin- yl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one (XI, EXAMPLE 150) the title compound is obtained.
  • R 2 or R 3 end is :
  • R 3 or R 4 end is:
  • n 2 is 3 or 4.
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 10-1 and R 10-2 are the same or different and are -H, C 1 -C 3 alkyl and where R 10-1 and R 10-2 taken together with the carbon atom to which they are attached form spirocyclopropyl
  • R 10-3 and R 10-4 are the same or different and are -H, C 1 -C 3 alkyl and where R 10-3 and R 10-4 taken together with the carbon atom to which they are attached form spirocyclopropyl, with CHART C - Continued
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 2 or R 3 end is: R 3 or R 4 end is:
  • R 2 or R 3 end is: R 3 or R 4 end is:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Des 5'-indolinyloxazolidine-2-ones de la formule (XI), 3-phényle (à substitution par combinaison cyclique condensée)-5beta-amidométhyloxazolidine-2-ones (XXI), et 3-phényle(à substitution azote)-5beta-amidométhyloxazolidine-2-ones (LV) sont des agents antibactériens utiles; et les intermédiaires (VI), (VII) et (VIII) sont utiles à leur production.
EP89909990A 1988-09-15 1989-08-22 5-beta-amidomethyle-oxazolidine-2-ones a substitution en position 3 Pending EP0434714A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24498888A 1988-09-15 1988-09-15
US244988 1988-09-15
US25385088A 1988-10-05 1988-10-05
US253850 1988-10-05
US32494289A 1989-03-17 1989-03-17
US324942 1989-03-17

Publications (1)

Publication Number Publication Date
EP0434714A1 true EP0434714A1 (fr) 1991-07-03

Family

ID=27399816

Family Applications (3)

Application Number Title Priority Date Filing Date
EP89909990A Pending EP0434714A1 (fr) 1988-09-15 1989-08-22 5-beta-amidomethyle-oxazolidine-2-ones a substitution en position 3
EP89308506A Expired - Lifetime EP0359418B1 (fr) 1988-09-15 1989-08-22 5-Indolinyl-5-bêta amidométhyloxazolidines-2-one, 3-(phényl condensé)-5 bêta amidométhyloxazolidines-2-ones et 3-phényl-azoté-5 bêta amidométhyloxazolidine 2-one
EP94102762A Expired - Lifetime EP0609905B1 (fr) 1988-09-15 1989-08-22 3-Phényl azoté-5-bêta-amidométhyl-oxazolidine-2-ones

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP89308506A Expired - Lifetime EP0359418B1 (fr) 1988-09-15 1989-08-22 5-Indolinyl-5-bêta amidométhyloxazolidines-2-one, 3-(phényl condensé)-5 bêta amidométhyloxazolidines-2-ones et 3-phényl-azoté-5 bêta amidométhyloxazolidine 2-one
EP94102762A Expired - Lifetime EP0609905B1 (fr) 1988-09-15 1989-08-22 3-Phényl azoté-5-bêta-amidométhyl-oxazolidine-2-ones

Country Status (14)

Country Link
EP (3) EP0434714A1 (fr)
JP (2) JP2865211B2 (fr)
KR (1) KR0138262B1 (fr)
AT (2) ATE112773T1 (fr)
AU (1) AU617871B2 (fr)
CA (1) CA1335103C (fr)
DE (2) DE68918792T2 (fr)
DK (2) DK175696B1 (fr)
ES (1) ES2157934T3 (fr)
GR (1) GR3036491T3 (fr)
HK (1) HK1002234A1 (fr)
LV (1) LV12888B (fr)
TW (1) TW219936B (fr)
WO (1) WO1990002744A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
IL98392A (en) * 1990-06-07 1996-01-19 Wellcome Found History of indole, their preparation and the pharmaceutical preparations containing them
DK0599968T3 (da) * 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
CA2136324A1 (fr) * 1992-07-08 1994-01-20 Steven Joseph Brickner 5'-indolinyloxazolidinones utiles pour la lutte contre le bacille de koch
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
SK282869B6 (sk) * 1994-10-26 2003-01-09 Pharmacia + Upjohn Company Antimikrobiálne fenyloxazolidinóny
WO1996015130A1 (fr) * 1994-11-15 1996-05-23 Pharmacia + Upjohn Company Agents antibacteriens du type oxazolidinone avec un substituant oxazine ou thiazine bicyclique
CN1075073C (zh) * 1995-02-03 2001-11-21 法玛西雅厄普约翰美国公司 杂芳环取代的苯基噁唑烷酮抗菌剂
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
CA2218088A1 (fr) * 1995-05-11 1996-11-14 Pharmacia & Upjohn Company Oxazolidinones a fraction diazinyle et carbazinyle spirocyclique et bicyclique
MX9703040A (es) * 1995-09-12 1997-07-31 Upjohn Co Antimicrobianos de feniloxazolidinona.
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601627A1 (de) * 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
GB9609919D0 (en) * 1996-05-11 1996-07-17 Zeneca Ltd Chemical compounds
US6218413B1 (en) 1997-05-30 2001-04-17 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
DE19730847A1 (de) * 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
GB9717807D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
AU739055B2 (en) * 1997-11-12 2001-10-04 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19802239A1 (de) * 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
KR20010015910A (ko) 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
NZ515754A (en) 1999-05-27 2003-10-31 Upjohn Co Bicyclic oxazolidinone compounds, pharmaceuticals thereof and their use as antibacterial agents
MXPA02000985A (es) 1999-07-28 2002-07-30 Upjohn Co Oxazolidinonas y su uso como antiinfecciosos.
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
CA2415965A1 (fr) 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises en tant qu'antimicrobiens
DE60121986T2 (de) 2000-10-02 2007-07-26 Emory University Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
PE20020689A1 (es) 2000-11-17 2002-08-03 Upjohn Co Oxazolidinonas con un heterociclo de 6 o 7 miembros unidos con enlace anular al benceno
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
GB0118407D0 (en) * 2001-07-27 2001-09-19 Cipla Ltd Oxazolidinone derivatives as antibacterial agents
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7012088B2 (en) * 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
EP1781642A1 (fr) * 2004-08-06 2007-05-09 Pharmacia & Upjohn Company LLC Oxazolidinones contenant des oxindoles en tant qu'agents antibacteriens
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
AU2006231919A1 (en) 2005-04-06 2006-10-12 Pharmacia & Upjohn Company Llc 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents
AU2006231918A1 (en) * 2005-04-06 2006-10-12 Pharmacia & Upjohn Company Llc An oxindole oxazolidinone as antibacterial agent
WO2009081148A1 (fr) * 2007-12-24 2009-07-02 Cipla Limited Procédé de synthèse de dérivés d'aminoindane propargylés
CA2794153C (fr) 2010-03-25 2018-01-02 Glaxosmithkline Llc Derives d'indoline substitue comme inhibiteurs de perk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES533097A0 (es) * 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1260948A (fr) * 1984-12-05 1989-09-26 E. I. Du Pont De Nemours And Company Derives d'aminomethyloxo-oxazolidinylbenzene, agents antibacteriens
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9002744A1 *

Also Published As

Publication number Publication date
JP2865211B2 (ja) 1999-03-08
DE68918792D1 (de) 1994-11-17
EP0359418A1 (fr) 1990-03-21
KR900701780A (ko) 1990-12-04
DK175696B1 (da) 2005-01-24
WO1990002744A1 (fr) 1990-03-22
DK45591D0 (da) 1991-03-13
AU4195789A (en) 1990-04-02
EP0609905B1 (fr) 2001-06-06
ES2157934T3 (es) 2001-09-01
TW219936B (fr) 1994-02-01
JPH04500665A (ja) 1992-02-06
JP3188418B2 (ja) 2001-07-16
DK175940B1 (da) 2005-08-01
ATE201870T1 (de) 2001-06-15
LV12888B (en) 2002-12-20
DK45591A (da) 1991-03-13
KR0138262B1 (ko) 1998-05-15
JPH1180139A (ja) 1999-03-26
DK200401246A (da) 2004-08-18
CA1335103C (fr) 1995-04-04
DE68918792T2 (de) 1995-03-30
AU617871B2 (en) 1991-12-05
DE68929303D1 (de) 2001-07-12
ATE112773T1 (de) 1994-10-15
EP0359418B1 (fr) 1994-10-12
DE68929303T2 (de) 2002-05-02
EP0609905A1 (fr) 1994-08-10
HK1002234A1 (en) 1998-08-07
GR3036491T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
EP0434714A1 (fr) 5-beta-amidomethyle-oxazolidine-2-ones a substitution en position 3
US5164510A (en) 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
AU667198B2 (en) Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US6107519A (en) Process to produce oxazolidinones
JP3255920B2 (ja) 置換ジアジン部分を含むオキサゾリジノン類とその殺菌剤としての利用
EP0788498A1 (fr) Composes antimicrobiens de phenyloxazolidinone
KR20020067557A (ko) 설폭시민 관능기를 가지는 옥사졸리디논 및항미생물제로서의 그의 용도
KR20010031953A (ko) 옥사졸리디논 유도체 및 제약 조성물
JP5662940B2 (ja) 新規な抗微生物薬
CA2515984A1 (fr) Indolone-oxazolidinones antibacteriens, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
EP0648119A1 (fr) UTILISATION DE 5'-INDOLINYLOXAZOLIDINONES CONTRE LE $i(MYCOBACTERIUM TUBERCULOSIS)
JP2002501073A (ja) 三環式インドレン置換オキサゾリジノン
EP0500686B1 (fr) Agents antibacteriens d'oxazolidinone tricycliques [6,5,5]/[6,6,5]-fusionnes
JP2000229978A (ja) オキサゾリジノン及び抗菌剤としてのそれらの使用
WO2008090570A1 (fr) Nouveaux antimicrobiens
KR100467309B1 (ko) 옥사졸리디논유도체및그의제조방법및항균제조성물
KR100365082B1 (ko) 불안증및수면장애치료용이미다조[1,5-a]퀴놀린

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19901128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89308506.8/0359418 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 26.08.91.